clinical trial · NCT07116616
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.·phase2·recruiting·n = 166
Relapsed or Refractory Multiple MyelomamRNA-2808
brief summary
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
started
Sep 30, 2025
primary completion
Jun 17, 2030
completion
Jun 17, 2032
last updated
Apr 3, 2026
official title
A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol